Fazarabine: a report of response in a patient with multiply relapsed embryonal cell carcinoma.
This report describes a patient with multiply relapsed and advanced metastatic embryonal cell carcinoma who achieved a pathological partial remission (PR) following treatment with a Phase I chemotherapeutic agent, arabinosyl-5-azacytosine (Ara-AC), followed by orchiectomy. The antimetabolic Ara-AC is worthy of further study in patients with germ-cell tumors. It would appear that the antimetabolite Ara-AC may have significant activity in patients with germ-cell tumors.
Johnston
P G
PG
Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20889.
Kleiner
D
D
Cowan
K H
KH
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use* / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000556:secondary*
D000970:Antineoplastic Agents; C022121:fazarabine; D001374:Azacitidine